Chemed (CHE) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CHE shares.
View CHE analyst ratings or view top-rated stocks.

1 equities research analysts have issued twelve-month target prices for Chemed's stock. Their CHE share price forecasts range from $610.00 to $610.00. On average, they anticipate the company's stock price to reach $610.00 in the next twelve months. This suggests a possible upside of 12.5% from the stock's current price.
View analysts price targets for CHE or view top-rated stocks among Wall Street analysts.

Chemed's stock was trading at $510.43 at the beginning of 2023. Since then, CHE shares have increased by 6.3% and is now trading at $542.41.
View the best growth stocks for 2023 here.

Chemed saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 474,700 shares, an increase of 21.9% from the April 30th total of 389,300 shares. Based on an average daily volume of 68,000 shares, the short-interest ratio is presently 7.0 days. Currently, 3.2% of the company's shares are sold short.
View Chemed's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023.
View our CHE earnings forecast.

Chemed Co. (NYSE:CHE) announced its earnings results on Friday, February, 24th. The company reported $5.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.30 by $0.09. The company earned $546.65 million during the quarter, compared to the consensus estimate of $546.60 million. Chemed had a trailing twelve-month return on equity of 37.83% and a net margin of 11.07%. The company's revenue was up 1.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $5.25 earnings per share.

Chemed announced a quarterly dividend on Monday, May 15th. Stockholders of record on Thursday, May 25th will be given a dividend of $0.38 per share on Wednesday, June 14th. This represents a $1.52 annualized dividend and a yield of 0.28%. The ex-dividend date is Wednesday, May 24th.
Read our dividend analysis for CHE.

ETFs with the largest weight of Chemed (NYSE:CHE) stock in their portfolio include VictoryShares THB Mid Cap ESG ETF (MDCP), Formidable Fortress ETF (KONG), AdvisorShares Dorsey Wright Alpha Equal Weight ETF (DWEQ), First Trust Dorsey Wright Momentum & Low Volatility ETF (DVOL), Inspire Faithward Mid Cap Momentum ETF (GLRY), Opus Small Cap Value Plus ETF (OSCV), QRAFT AI-Enhanced U.S. Large Cap Momentum ETF (AMOM) and Dividend Performers ETF (IPDP).

Chemed (NYSE:CHE) pays an annual dividend of $1.52 per share and currently has a dividend yield of 0.28%. The company has been increasing its dividend for 14 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 9.57%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CHE will have a dividend payout ratio of 6.71% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for CHE.

1 employees have rated Chemed Chief Executive Officer Kevin J. McNamara on Glassdoor.com. Kevin J. McNamara has an approval rating of 100% among the company's employees. This puts Kevin J. McNamara in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include AT&T (T), Home Depot (HD), Johnson & Johnson (JNJ), AbbVie (ABBV), Abbott Laboratories (ABT), CVS Health (CVS), Boeing (BA), UnitedHealth Group (UNH), Verizon Communications (VZ) and Chevron (CVX).

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Chemed's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.28%), William Blair Investment Management LLC (3.73%), Neuberger Berman Group LLC (3.55%), Kayne Anderson Rudnick Investment Management LLC (3.40%), Envestnet Asset Management Inc. (3.18%) and State Street Corp (2.95%). Insiders that own company stock include David Patrick Williams, Donald E Saunders, Kevin J Mcnamara, Michael D Witzeman, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee and Thomas P Rice.
View institutional ownership trends.

Shares of CHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CHE stock can currently be purchased for approximately $542.41.

Chemed (NYSE:CHE) has a market capitalization of $8.15 billion and generates $2.13 billion in revenue each year. The company earns $249.62 million in net income (profit) each year or $15.89 on an earnings per share basis.

The company employs 14,167 workers across the globe.

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The official website for the company is www.chemed.com. The company can be reached via phone at (513) 762-6690 or via fax at 513-762-6590.